Obstruction of St. jude medical valves in the aortic position: Plasma transforming growth factor type beta 1 in patients with pannus overgrowth

Artificial Organs

Volumn 34, Issue 3, 2010, Pages 210-215

  Teshima, Hideki ^a   Fukunaga, Shuji ^a   Takaseya, Tohru ^a   Tomoeda, Hiroshi ^a   Akashi, Hidetoshi ^a   Aoyagi, Shigeaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

International normalized ratio; Pannus overgrowth; Prosthesis; Transforming growth factor beta; Valve; Warfarin

Indexed keywords

BLOOD VESSELS;

AORTIC POSITION; CONTROL GROUPS; INTERNATIONAL NORMALIZED RATIOS; PANNUS OVERGROWTH; PROTHROMBIN TIME; ST. JUDE MEDICAL; TGF-Β1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTORS; WARFARIN;

PROSTHETICS;

ANTICOAGULANT AGENT; TRANSFORMING GROWTH FACTOR BETA1; WARFARIN;

ADULT; AORTA VALVE DISEASE; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; AORTIC VALVE OBSTRUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PANNUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; TREATMENT WITHDRAWAL;

EID: 77949771792     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00800.x     Document Type: Article

References (33)

1. Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. Ann Thorac Surg 2005 79 : 776 783.
2. Deveri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 1991 17 : 646 650.
3. Vitale N, Renzulli A, Agozzino L, et al. Obstruction of mechanical mitral prostheses: analysis of pathological findings. Ann Thorac Surg 1997 63 : 1101 1106.
4. Rizzoli G, Guglielmi C, Toscano G, et al. Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk. Eur J Cardiothorac Surg 1999 16 : 74 80.
5. Lengyel M. Management of prosthetic valve thrombosis. J Heart Valve Dis 2004 13 : 329 334.
6. Aoyagi S, Nishimi Y, Tayama E, et al. Obstruction of St. Jude Medical valves in the aortic position: a consideration for pathogenic mechanism of prosthetic valve obstruction. Cardiovasc Surg 2002 10 : 339 344.
7. Ibrahim MF, David TE. Mitral stenosis after mitral valve repair for nonrheumatic mitral regurgitation. Ann Thorac Surg 2002 73 : 34 6.
8. Renzulli A, Luca LD, Verde CR, Galzerano D, Cotrufo M. Acute thrombosis of prosthetic valve: a multivariate analysis of the risk factors for a life-threatening event. Eur J Cardiothoracic Surg 1992 6 : 412 421.
9. Yoganathan AP, Corcoran WH, Harrison EC, Carl JR. The Bjork-Shiley aortic prosthesis: flow characteristics, thrombus formation and tissue overgrowth. Circulation 1978 58 : 70 6.
10. Toker ME, Eren E, Balkanay M, et al. Multivariate analysis for operative mortality in obstructive prosthetic valve dysfunction due to pannus and thrombus formation. Int Heart J 2006 47 : 237 245.
11. Ozeren M, Demirpence O, Han U, Dogan OV, Yucel E, Onal B. Effect of fibroblast growth factor-2 on pannus formation in replacement prosthetic heart valves. J Heart Valve Dis 2004 13 : 676 680.
12. Aoyagi S, Nishimi Y, Kawano H, et al. Obstruction of St. Jude Medical valves in the aortic position: significance of a combination of cineradiography and echocardiography. J Thorac Cardiovasc Surg 2000 120 : 142 147.
13. Tayama E, Aoyagi S. Asymptomatic prosthetic valve dysfunction. Artif Organs 2002 26 : 399 401.
14. Teshima H, Hayashida N, Fukunaga S, et al. Usefulness of a multidetector-row computed tomography scanner for detecting pannus formation. Ann Thorac Surg 2004 77 : 523 526.
15. Teshima H, Hayashida N, Yano H, et al. Obstruction of St. Jude Medical valves in the aortic position: histology and immunohistochemistry of pannus. J Thorac Cardiovasc Surg 2003 126 : 401 407.
16. Teshima H, Hayashida N, Nishimi M, et al. Thrombolytic therapy with tissue plasminogen activator for the treatment of nonstructural malfunction of bileaflet cardiac valve prostheses. Artif Organs 2002 26 : 460 466.
17. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986 58 : 427 444.
18. Border WA, Noble NA, Epstein FH. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994 10 : 1286 1292.
19. Shi Y, O'Brien JE Jr., Fard A, Zalewski A. Transforming growth factor-beta1 expression and myofibroblast formation during arterial repair. Arterioscler Thromb Vasc Biol 1996 16 : 1298 1305.
20. Jian B, Narula N, Li Q, Mohler ER 3rd., Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003 75 : 457 466.
21. Watson KE, Bostorm K, Ravindranath R, et al. TGF-beta1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994 93 : 2106 2113.
22. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999 8 : 93 7.
23. Lee TY, Chin GS, Kim WJH, Gittes GK, Longaker MT. Expression of transforming growth factor beta 1, 2 and 3 proteins in keloids. Ann Plast Surg 1999 43 : 179 184.
24. Mori T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement - optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg 2002 8 : 83 7.
25. Uetsuka Y, Hosoda S, Kasanuki H, et al. Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to PT-INR. Heart Vessels 2000 15 : 124 128.
26. Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998 28 : 439 446.
27. Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-β1 levels. Nat Med 1997 3 : 1209 1215.
28. Polo M, Ko F, Busillo F, Cruse CW, Krizek TJ, Robson MC. Cytokine production in patients with hypertrophic burn scars. J Burn Care Rehabil 1997 18 : 477 482.
29. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999 33 : 271 275.
30. Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007 71 : 761 765.
31. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007 167 : 239 245.
32. Koertke H, Zittermann A, Tenderich G, et al. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J 2007 28 : 2479 2484.
33. Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002 123 : 715 723.